A symposium focusing on high-quality developments being undertaken by Taixing city in Jiangsu province took place in Shanghai on June 27, discussing the current situation and exploring the future development of the biopharmaceutical industry.
As a main area for the development of the pharma sector in Taixing, the Taixing Economic Development Zone has established a production base for active pharmaceutical ingredients with a total area of 5.61 square kilometers.
Demarcating a built-up area, a planning area and an expansion area, the zone has built a pharma industry cluster covering key areas such as biopharmaceuticals and chemical active pharmaceutical ingredients (APIs) and preparations. It has also managed to help cultivate a raft of star performing pharmaceutical innovation enterprises based there.
A signing ceremony takes place during the symposium. [Photo/WeChat account: txfabu]
At the symposium, the zone signed an agreement with Dongjun Biotechnology for the modernization of R&D and production facilities for traditional Chinese medicine. It also signed an agreement with Aishen Biotechnology for a surface plasmon resonance molecular interactor project.
The advantages of the zone's investment environment were also presented to the symposium. One example is that the zone has built a full chain technology innovation service platform covering R&D, small-scale testing and pilot testing.
What's more, a government industry guidance fund with a scale of 2 billion yuan ($279.24 million) and a market-oriented pharmaceutical industry fund with a scale of 2.01 billion yuan have been set up to provide flexible funding support for projects.